Author:
Piranavan Paramarajan,Perl Andras
Funder
National Institutes of Health
National Institute of Allergy and Infectious Diseases
Central New York Community Foundation
Subject
Immunology,Immunology and Allergy
Reference17 articles.
1. Two-year, randomized, controlled trial of Belimumab in lupus nephritis;Furie;N. Engl. J. Med.,2020
2. OP0277 AURORA phase 3 study demonstrates Voclosporin statistical superiority over standard of Care in Lupus Nephritis (LN);Arriens;Ann. Rheum. Dis.,2020
3. Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases;Perl,2016
4. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus;Fernandez;Arthritis Rheum.,2006
5. Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial;Lai;Lancet.,2018
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献